Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, today announced the presentation of preclinical data that supported the completed Phase 1a trial of AP02 (inhaled nintedanib) as well as clinical data for AP01 (inhaled pirfenidone) at the 2023 Pulmonary Fibrosis Foundation (PFF) Summit at the JW Marriott Grande Lakes in Orlando, FL.
- “We are excited to engage with the pulmonary fibrosis community at the PFF Summit, including people living with the disease, their caregivers and the expert providers that support them, and to share data for our inhaled treatment candidates AP01 and AP02,” said Howard M. Lazarus, M.D.
- These data demonstrated that inhaled nintedanib was well-tolerated, was indicative of efficient inhaled alveolar deposition, and delivered oral-superior lung levels with reduced systemic exposure.
- Avalyn will also review the results from the Phase 1b trial of AP01 (ATLAS) in participants with idiopathic pulmonary fibrosis (IPF).
- The OLE enrolled ATLAS participants and AP01-naïve pulmonary fibrosis participants, and the data showed a durable and consistent response to AP01, including fewer reported adverse events compared to historical reports of oral pirfenidone.